Several factors that predict the outcome of large B‐cell lymphoma patients who relapse/progress after chimeric antigen receptor ( CAR ) T‐cell therapy can be identified before cell administration
Cancer Medicine · 2024
DOI: 10.1002/cam4.70138 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Alice Sýkorová und 24 weiteren Autor:innen. Beteiligte Einrichtung: 4th Department of Internal Medicine - Haematology, University Hospital and Faculty of Medicine, Hradec Králové, Czech Republic. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: grant AZV NU21-03-00411 from the Ministry of Health of the Czech Republic, This work was supported by the Ministry of Health, Czech Republic under grant MH CZ-DRO (UHHK, 00179906), under grant AZV NU21-03-00411 and by Charles Universi….
Abstract (Originalsprache)
Aim
The aim of this study was to analyse the outcomes of patients with large B‐cell lymphoma (LBCL) treated with chimeric antigen receptor T‐cell therapy (CAR‐Tx), with a focus on outcomes after CAR T‐cell failure, and to define the risk factors for rapid progression and further treatment.
Methods
We analysed 107 patients with LBCL from the Czech Republic and Slovakia who were treated in ≥3rd‐line with tisagenlecleucel or axicabtagene ciloleucel between 2019 and 2022.
Results
The overall response rate (ORR) was 60%, with a 50% complete response (CR) rate. The median progression‐free survival (PFS) and overall survival (OS) were 4.3 and 26.4 months, respectively. Sixty‐three patients (59%) were refractory or relapsed after CAR‐Tx. Of these patients, 39 received radiotherapy or systemic therapy, with an ORR of 22% (CR 8%). The median follow‐up of surviving patients in whom treatment failed was 10.6 months. Several factors predicting further treatment administration and outcomes were present even before CAR‐Tx. Risk factors for not receiving further therapy after CAR‐Tx failure were high lactate dehydrogenase (LDH) levels before apheresis, extranodal involvement (EN), high ferritin levels before lymphodepletion (LD) and ECOG PS >1 at R/P. The median OS‐2 (from R/P after CAR‐Tx) was 6.7 months (6‐month 57.9%) for treated patients and 0.4 months (6‐month 4.2%) for untreated patients ( p < 0.001). The median PFS‐2 (from R/P after CAR‐Tx) was 3.2 months (6‐month 28.5%) for treated patients. The risk factors for a shorter PFS‐2 ( n = 39) included: CRP > limit of the normal range (LNR) before LD, albumin < LNR and ECOG PS > 1 at R/P. All these factors, together with LDH > LNR before LD and EN involvement at R/P, predicted OS‐2 for treated patients.
Conclusion
Our findings allow better stratification of CAR‐Tx candidates and stress the need for a proactive approach (earlier restaging, intervention after partial remission achievement).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 4th Department of Internal Medicine - Haematology, University Hospital and Faculty of Medicine, Hradec Králové, Czech Republic.
- Department of Internal Medicine, Haematology and Oncology, Masaryk University Hospital, Brno, Czech Republic.
- 1st Department of Medicine-Department of Haematology, Charles University, General University Hospital, Prague, Czech Republic.
- Department of Haematology, University Hospital Královské Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic.
- Department of Haemato-oncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
- Department of Haematology and Oncology, University Hospital, Pilsen, Czech Republic.
ORCID-Profile: Alice Sýkorová
Förderung
- grant AZV NU21-03-00411 from the Ministry of Health of the Czech Republic
- This work was supported by the Ministry of Health, Czech Republic under grant MH CZ-DRO (UHHK, 00179906), under grant AZV NU21-03-00411 and by Charles Universi…
Zitieren
APA
Sýkorová, A., Folber, F., Polgárová, K., Móciková, H., Ďuraš, J., Steinerová, K., Obr, A., Heindorfer, A., Ladická, M., Lukáčová, Ľ., Čellárová, E., Plameňová, I., Belada, D., Janíková, A., Trněný, M., Jančárková, T., Procházka, V., Vranovský, A., Králiková, M., …, & Pytlík, R. (2024). Several factors that predict the outcome of large B‐cell lymphoma patients who relapse/progress after chimeric antigen receptor ( CAR ) T‐cell therapy can be identified before cell administration. Cancer Medicine. https://doi.org/10.1002/cam4.70138
Vancouver
Sýkorová A, Folber F, Polgárová K, Móciková H, Ďuraš J, Steinerová K, et al. Several factors that predict the outcome of large B‐cell lymphoma patients who relapse/progress after chimeric antigen receptor ( CAR ) T‐cell therapy can be identified before cell administration. Cancer Medicine. 2024. doi:10.1002/cam4.70138
BibTeX
@article{Skorov2024,
author = {Sýkorová, Alice and Folber, František and Polgárová, Kamila and Móciková, Heidi and Ďuraš, Juraj and Steinerová, Kateřina and Obr, Aleš and Heindorfer, Adriana and Ladická, Miriam and Lukáčová, Ľubica and Čellárová, Erika and Plameňová, Ivana and Belada, David and Janíková, Andrea and Trněný, Marek and Jančárková, Tereza and Procházka, Vít and Vranovský, Andrej and Králiková, Margaréta and Vydra, Jan and Smolej, Lukáš and Drgoňa, Ľuboš and Sedmina, Martin and Čermáková, Eva and Pytlík, Robert},
title = {Several factors that predict the outcome of large B‐cell lymphoma patients who relapse/progress after chimeric antigen receptor ( CAR ) T‐cell therapy can be identified before cell administration},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.70138}
}
EUVIMED